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Abstract Leber's hereditary optic neuropathy (LHON) is a maternally inherited isease associated with point mutations in mitochondrial DNA. 
The most frequent of these mutations i  the G-to-A substitution at nucleotide position 11,778 which changes an evolutionarily conserved arginine 
with a histidine at position 340 in subunit ND4 of NADH : ubiquinone reductase (respiratory complex I). We report hat this amino acid substitution 
alters the affinity of complex I for the ubiquinone substrate and induces resistance towards its potent inhibitor otenone in mitochondria of LHON 
patients. Such changes could reflect a substantial loss in the energy conserving function of NADH: ubiquinone reductase and thus explain the 
pathological effect of the ND4/11,778 mutation. 
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1. Introduction 
Leber's hereditary optic neuropathy (LHON) is a maternally 
inherited isease which is clinically characterized by the sudden 
loss of central vision and affects prevalently oung males [1]. 
To date, several point mutations in mitochondrial DNA 
(mtDNA) have been associated with LHON [1-3]. The most 
frequent of these mutations [1-3] is the substitution at nucleo- 
tide position (np) 11,778 in the ND4 subunit of complex I [4--6]. 
The functional defect hat arises from the amino acid substitu- 
tion (Arg34°---~His [4]) caused by this mutation is not clear yet 
[4,6-8], even if a recent report has shown a 25% decrease in 
complex I activity measured with a short analogue of ubiqui- 
none [9]. In contrast, the LHON mutation ND1/3460 has been 
shown to induce a strong decrease in the activity of complex 
I [7,9,10]. 
We report here that the ND4/11,778 mutation induces resis- 
tance to rotenone, which is the classical potent inhibitor of 
complex I [11-13], and alters the reaction of the complex with 
the ubiquinone substrate. The alteration in both rotenone po- 
tency and ubiquinone affinity indicate that the major functional 
defect in patients with this LHON mutation is at the energy 
conserving site of  complex I. 
2. Materials and methods 
Platelet mitochondria were isolated from several unrelated control 
individuals and three affected members (Fig. 1A) of a large LHON 
family from Northern Italy [6]. The platelets were purified from 100 ml 
of venous blood [14], and mitochondrial particles were prepared by 
sonication in 0.1 M Tris-HCl, pH 7.4, containing 1mM EDTA. After 
centrifugation at 10,000 rpm for 10 min in an Eppendorf microcentri- 
fuge, the supernatant was diluted threefold with 0.25 M sucrose, 50 mM 
Tricine-HCl, pH 7.6, containing 30 mM KCI, 5 mM MgCI 2 and 0.5% 
bovine serum albumin, and centrifuged at 100,000 x g to precipitate 
mitochondrial particles, which were resuspended in the same sucrose- 
Tricine buffer at 6-12 mg/ml of protein, measured by the Lowry 
method. The preparation was immediately used in the biochemical 
assays. 
The NADH: quinone reductase activity was measured at 37°C with 
150 NM NADH and 30/tM 2,3-dimethoxy-5-methyl-6-n-undecyl-p- 
benzoquinone (UBQ [15], a generous gift of E. Berry, University of 
California t Berkeley, USA) or ubiquinone-2 (Q2, a gift from Eisai Co., 
Tokyo, Japan) as detailed recently [16]. The activities of ubiquinol- 
2:cytchrome c reductase and NADH:ferricyanide reductase were 
assayed at 30°C in the same buffer used for the NADH: quinone reduc- 
tase assay (50 mM K-phosphate, pH 7.6, containing 10 mM KCN and 
1 m M EDTA) as described in [16]. The inhibitory effect of rotenone was 
assayed by incremental amounts of a concentrated solution to the 
mitochondrial suspension as in [16]. The potency of rotenone and other 
inhibitors was expressed as the final concentration of inhibitor in the 
assay that yielded 50% inhibition of NADH oxidation by UBQ (150). 
mtDNA was extracted from the same platelet samples utilized to 
prepare the mitochondrial particles by the standard phenol/chloroform 
method [6]. A 119 bp mtDNA fragment encompassing the np 11,778 
site was amplified by PCR using primers L11720-11740 and H11820- 
11839 [4,6,17]. The presence of the 11778 G-to-A transition [4] was 
detected with 100% specificity by the combined use of the restriction 
enzymes SfaNI (loss of a restriction site) and MaelII (creation of a new 
restriction site) [17]. mtDNA fragments were separated by 3% Nu-Sieve 
and 0.5% agarose gels (Figs 1B and C). 
The analysis of the deduced amino acid sequences of the ND4 sub- 
unit has been carried out with the methods utilized previously for 
cytochrome b [18,19]. 34 complete sequences from mitochondrial, plas- 
tidial and bacterial species were taken from recent versions of the 
EMBL data banks and aligned as in [19]. The average hydropathy and 
amphipathy profile of the aligned sequences confirmed the analysis in 
[20] except hat the region corresponding to the previously proposed 
helix H [20] was not predicted to be transmembranous. 
The consensus sequences ofthe ND4 subunit and cytochrome b were 
obtained by analyzing 20 mitochondrial sequences from the same set 
of species plus that of E. coli for ND4 and that of R. rubrum for 
cytochrome b.Sequence similarity with a database of quinone-reacting 
peptides was evaluated as described previously [18]. The complete align- 
ments are available from the Authors. 
3. Results and discussion 
*Corresponding author. Department of Biology, University of 
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3.1. Complex I of LHON patients is resistant o rotenone 
The biochemical defect in complex I consequent on the ND4/  
11778 mutation was determined by the specific activity of 
NADH:  ubiquinone (Q) reductase in platelet mito- 
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only 25% [9] decrease in the NADH:Q reductase activity of 
complex I. We also did not observe significant changes of com- 
plex I activity in LHON patients with respect to control individ- 
uals (results not shown). However, we found that the 
NADH:Q reductase activity in LHON patient has a 
clearly altered sensitivity to rotenone (Fig. 2). The 15o of ro- 
tenone is dependent upon the protein concentration in the assay 
[13,14,16] and has an average value of 35 pmol per mg of 
protein in platelet mitochondria of healthy individuals. This 150 
of rotenone increases over threefold (Figs. 2 and 3) in the 
patients with the ND4/11778 mutation. In addition to the de- 
creased sensitivity to rotenone, patients with the ND4/11778 
mutation also show a change in affinity for the ubiquinone 
substrates (Fig. 3). The Km for undecyl-ubiquinone decreases 
from an average of 17 pM in the controls to an average of 
8 pM in the LHON patients, whereas the Km for Q2 increases 
from 2 to 7 pM (Fig. 3). Unlike UBQ and other quinones with 
saturated hydrocarbon chains, Q2 functions both as a substrate 
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Fig. l. (A) Pedigree of the Italian LHON family [6] investigated. The 
symbol * marks the three affected individuals studied. Twelve asympto- 
matic family members, all along the matrilinear linage, also harbor the 
ND4/11778 mutation, while four children of an affected male, as ex- 
pected, lack the mutation. Molecular investigation has not been per- 
formed on individuals 11-4 and 11-6. (B and C) Molecular confirmation 
of the virtually homoplasmic ND4/11778 mutation i  all three affected 
individuals. The amplified fragment of 119 bp remains uncut with 
SfaNI (site loss) and is cut with MaelII (new site creation) in LHON 
individuals. Note that SfaNl and MaelII cut, respectively, wild-type 
(controls) and mutated (LHON) mtDNA in two different sites sepa- 
rated by 13 nucleotides. 
chondrial particles from the affected members of an Italian 
family carrying this mutation [4] (Fig. 1A). The mtDNA of the 
three individuals with LHON investigated was virtually homo- 
plasmic for the ND4/11778 mutation (Fig. 1B and C) and no 
other known LHON mutation has been detected in the mtDNA 
of this family (data not shown). 
The function of complex I has been measured with the un- 
decyl analog of ubiquinone [15] which, contrary to other qui- 
nones [16], elicits a reaction that is fully sensitive to rotenone 
(Fig. 2), the classical potent inhibitor of complex I that interacts 
as a ubiquinone antagonist [11-13]. Previous studies on mito- 
chondria isolated from patients having the ND4/11778 muta- 
tion found a substantial decrease in respiratory rates of NAD- 
linked substrates such as glutamate, but showed little [7,8] or 
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Fig. 2. Rotenone titration of NADH : ubiquinone r ductase activity of 
platelet mitochondria from normal individuals (open circles) and 
LHON patients (fill circles). (A) 0.12 mg/ml of mitochondrial protein 
for one control and 0.1 mg/ml of mitochondrial protein of one LHON 
patient 1[4]. (B) Average data with 0.07 mg/ml ofmitochondrial protein 
from two normal individuals and 0.08 mg/ml of mitochondrial protein 
from patient 2 of the same LHON family [6]. The specific activity of 
NADH:UBQ reductase (average rate of 15 nmol/min per mg protein, 
cf. [10]), NADH: ferricyanide and ubiquinol: cytochrome c reductase 
[16] were comparable incontrol individuals and in the members of the 
LHON family (cf. [6]). 
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and as an inhibitor of mammalian complex I [21,22], presuma- 
bly because it competes for the site where rotenone antagonizes 
ubiquinone and its intermediates [12]. Following this interpre- 
tation, the parallel increase in the 15o of rotenone and in the Km 
for Q2 (Fig. 3) could reflect the same functional alteration in 
the reaction of complex I with its natural ubiquinone substrate. 
The 150 of stigrnatellin, a ubiquinone-like inhibitor of various 
quinone reacting systems including complex I [23], is also in- 
creased in the mitochondria of patients with LHON (Fig. 3), 
whereas the 150 of the barbiturate amytal, an inhibitor of com- 
plex I which is structurally unrelated to ubiquinone [11-13], is 
not changed (Fig. 3). Hence, the functional lesion of the ND4/ 
11778 mutation can be localized to the site at which ubiquinone 
binds to complex I. 
3.2. Relationship between structure and function of the ND4 
subunit 
The resistance towards rotenone in mitochondria carrying a 
mutated amino acid in the ND4 subunit suggests that this 
subunit may be involved in the binding of rotenone to complex 
I. Previously, the binding of a radiolabelled analog of rotenone 
was associated to another subunit of the complex, namely ND 1 
[20]. However, rotenone binds to complex I in a complicated 
way, because two binding sites are present and several subunits 
could form such a binding site (see [13,21] and references 
therein). It is therefore possible that both the ND 1 and the ND4 
subunits are involved in rotenone binding. 
The ND4 subunit is a hydrophobic protein which spans the 
membrane at least ten times [21]. It may be involved in the 
proton pumping function of complex I since it possesses evolu- 
tionarily invariant residues with ionizable that lie within the 
helices which are predicted to cross the membrane [21]. Accord- 
ing to the folding model elaborated by multiple sequence anal- 
ysis [18,19] (Fig. 4A), Arg 34° lies at the beginning of the trans- 
membrane helix J [21] near the negative (matrix) side of the 
membrane. The protein region preceding Arg 34° at the negative 
side of the membrane shows some sequence similarity with 
quinone-reacting peptides of membrane complexes such as cy- 
tochrome b of ubiquinol:cytochrome c reductase [18,19] (Fig. 
4B). Within this region an interesting sequence match is seen 
between the highly conserved His 319 of ND4 and the invariant 
His 2°2 (yeast numbering [19]) of mitochondrial cytochrome b,
the latter being involved in the interaction with the ubisemiqui- 
none intermediate that is formed during ubiquinol oxidation 
[25,26]. A clear sequence similarity is also found between the 
region following His 319 in ND4 and that following His 2°2 in 
cytochrome b, which are both predicted to lie at the negative 
side of the membrane (Fig. 4). This section of cytochrome b 
contains everal point mutations conferring resistance to ubiq- 
uinone antagonists uch as antimycin [19,25-27] (Fig. 4B). 
Structural similarities of this kind suggest common functional 
properties for the ND4 subunit and cytochrome b, which are 
both encoded by mtDNA. It is thus inferred that ND4 may be 
involved in the binding of the ubisemiquinone intermediate hat 
is also formed in the oxidation of NADH by complex I [28,29]. 
Protein-bound ubisemiquinone anions are stabilized by pos- 
itively charged amino acids such as arginine [26,30,31], and the 
replacement of an arginine with a less basic histidine, as arises 
from the ND4/11778 mutation, may reduce the stability of 
ubisemiquinone bound to complex I [30,31]. Indeed, the re- 
placement of His 2°2 with an Arg in bacterial cytochrome b 
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Fig. 3. Relative ratio of affinities for ubiquinone substrates and inhib- 
itors of complex I in control individuals and LHON patients. The 
average values of the parameters in 8 control individuals were as fol- 
lows. Ki rotenone, 1nM (extrapolated from the mean protein depend- 
ence of the/5o); 150 of rotenone, 35 pmol/mg protein; Km of Q2 as a 
substrate, 2/tM; Km of UBQ, 20/IM; 150 of stigmatellin, 4.2/.tM; and 
150 of amytal, 0.25 mM. 
increases the stability of bound ubisemiquinone by approxi- 
mately one order of magnitude [26]. The stability of ubisemiq- 
uinone is dictated by its dismutation reaction according to the 
equation [26,29-32]: 
[Q.-]2 
Ks = [Q]" [Q2-] 
where Ks is the stability constant of the semiquinone radical 
anion (Q'), Q is the oxidized quinone and Q2- is the reduced 
quinone dianion. If the changes in the Km for ubiquinone-2 and 
in the 150 of rotenone (Fig. 3) are taken as an estimation of the 
decrease in the binding of ubisemiquinone, the stability con- 
stant for the protein-bound ubisemiquinone consequently de- 
creases by at least one order of magnitude [26,31]. This implies 
a decrease in the redox potential of bound ubisemiquinone (ca. 
-110 mV [31]) by at least 60 mV [26,30,31] with a considerable 
loss of energy because of the reduced ifference in redox poten- 
tial between the intermediate ubisemiquinone and the electron 
donor NADH (E m = -320 mV). Hence, less free energy is 
available to be converted into proton pumping and ultimately 
into ATP synthesis during the oxidation of NADH by the 
LHON-mutated complex I. The decrease in energetic efficiency 
of this altered complex I, although partial, may become critical 
with ageing and/or in relation to other aetiological factors (see 
[1-10] for discussion of these factors). 
4. Conclusions 
The present results and their interpretation suggest that the 
usual ND4/11778 mutation causing Leber's hereditary optic 
neuropathy [4,5] produces a loss of the redox energy developed 
by the reaction of complex I with ubiquinone. A reduced stabil- 
ity of the ubisemiquinone intermediate due to the replacement 
of Arg ~° with His could be responsible for the decrease in the 
energy-conserving function of complex I. The less stable 
ubisemiquinone radical dismutates rapidly and reacts directly 
with oxygen to form radicals that may contribute to further 
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Fig. 4. (A) Hypothetical model for the folding of the ND4 subunit of mitochondrial complex I with the residues that appear to be invariant in all 
the aligned sequences. The nomenclature of the predicted transmembrane helices conforms to that proposed previously [21]. His 3w is highlighted by 
a hatched pentagon. The region which shows the highest sequence homology with the ND5 subunit [21] is also marked. The negative side of the 
membrane corresponds to the matrix of mitochondria. (B) Alignment of the consensus sequence of mitochondrial nd bacterial ND4 proteins to 
the consensus sequence of mitochondrial nd bacterial cytochrome b apoprotein i  a central region at the negative side of the membrane [19]. The 
symbol * marks the positions of the mutations which confer esistance towards ubiquinone antagonists such as antimycin, funiculosin and diuron 
[19]. The symbol @ marks the positions where mutations induce respiratory deficiency [19,27]. Identical amino acids in the two consensus sequences 
are marked by =,  chemically similar amino acids by., and conserved amino acids with positive or negative charge are marked by + or -,  respectively. 
The gap in the consensus of cytochrome b is required for maximal identity also in the aligned sequences of this protein [19]. 
mitochondrial damage. Such a 'short circuit' in electron trans- 
port might not be detectable in the assay of NADH oxidation 
by exogenous ubiquinones, ince rapid autoxidation continu- 
ously regenerates the ubiquinone acceptor. It could become 
evident, however, in the integrated electron transport along the 
respiratory chain, because rapid autoxidation of ubisemiqui- 
none also implies a decreased efficiency in releasing the ubiq- 
uinol product by the mutated complex I. This may explain why 
NAD-l inked substrates are oxidized at lower rates in mitochon- 
dria of LHON patients than in those of control individuals 
[7,8], although other explanations have been advanced [7]. 
In conclusion, the significance of this work is twofold. First, 
the functional alteration associated with the most common 
LHON mutation is shown to lie at the site of interaction be- 
tween complex I and its substrate ubiquinone, and thus it could 
be corrected by therapies using appropriate quinones [32]. Sec- 
ond, the domain of the ND4 subunit containing Arg 34° is likely 
to be involved in the binding of rotenone and ubiquinone, 
M. Degli Esposti et al./FEBS Letters 352 (1994) 375-379 379 
thereby assigning a functional role to this subunit of complex 
I for the first time. 
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